AMPLITUDE-O: Efpeglenatide Benefits in High-Risk Diabetes ...Middle East

In older patients with long-time type 2 diabetes and CVD or kidney disease, the investigational GLP-1 agonist efpeglenatide was safe and lowered the risk of CV events in AMPLITUDE-O. Medscape Medical News

Hence then, the article about amplitude o efpeglenatide benefits in high risk diabetes was published today ( Tuesday 29/06/2021 - 06:47 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AMPLITUDE-O: Efpeglenatide Benefits in High-Risk Diabetes )

Also on site :

• Your spend as a ‘weapon’: Scott Galloway’s ‘Resist and Unsubscribe’ movement asks you to ditch Amazon, Apple, and Netflix to oppose Trump
• 'Any Updates?' Chuck Schumer's Post Last Year Accusing Trump of Being Weak on Iran Has Aged Wonderfully
• Conventional Wisdom: Let’s Make a Deal Edition